Spontaneous clearance and treatment of acute hepatitis C infection in HIV-positive men with 48 weeks of interferon-alpha and Ribavirin

Webster, Daniel P.; Wojcikiewicz, T.; Keller, Majella; Castelnovo, D; Mistry, Haleigh; Gilleece, Yvonne; Tibble, Jeremy; Fisher, Martin

doi:10.1177/0956462412472317

Cited by 13 publications

(20 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the 8 studies with ITT analysis [6,38,39,40,43,46,47,48], 189 of 258 patients achieved an SVR (73.2%; 95% CI 64.2-80.5). Four [41,42,44,45 ]studies without ITT analysis reported treatment success in 134 of 192 patients (68.9%; 95% CI 56.7-78.9) [41,42,44,45].…”

Section: Resultsmentioning

confidence: 99%

“…Eight were prospective in study design [6,38,39,41,44,45,47,48]. Most studies [6,38,39,40,43,46,47,48] featured an ITT analysis. One study [46] included 3 patients who were each treated twice for 2 separate a-HCV infections.…”

Section: Resultsmentioning

confidence: 99%

“…Most studies [6,38,39,40,43,46,47,48] featured an ITT analysis. One study [46] included 3 patients who were each treated twice for 2 separate a-HCV infections. Another study [44] included 3 patients who were also positive for hepatitis B and 2 who were treated with only peginterferon.…”

Section: Resultsmentioning

confidence: 99%

“…1). Ten studies (83%) originated from Europe [6,38,39,40,41,42,43,44,45,46], mostly from the UK [38,40,41,45,46] and France [6,39,44]. Eight were prospective in study design [6,38,39,41,44,45,47,48].…”

Section: Resultsmentioning

confidence: 99%

“…Two studies used 12 months between positive and negative serologies in their definition [44,46]. One study used 3 months [38], another used 8 months [6], and a third used 2 years [44].…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Treatment of Acute Hepatitis C Infection with Pegylated Interferon and Ribavirin in Patients Coinfected with Human Immunodeficiency Virus: A Systematic Review and Meta-Analysis

Zhang

Nguyen²,

Yee³

et al. 2015

Intervirology

View full text Add to dashboard Cite

Background/Aims: Of the 35 million human immunodeficiency virus (HIV)-positive patients worldwide, 10-40% are coinfected with chronic hepatitis C virus (HCV). Compared to HCV-monoinfected patients, those coinfected experience decreased spontaneous HCV clearance, accelerated liver fibrosis, and a decreased response to anti-HCV therapy. We conducted a meta-analysis to estimate the efficacy of treating acute HCV in HIV-positive patients with peginterferon and ribavirin combination therapy. Methods: Two authors independently searched MEDLINE and EMBASE (2014) for English articles, and reviewed bibliographies and abstracts from major liver and HIV conferences (2011-2013). Original studies featuring at least 10 treatment-naive, HIV-positive adults infected with acute HCV and treated with peginterferon and ribavirin were included. Analyses were calculated using a random-effects model. Heterogeneity was assessed using the Cochrane Q test (p < 0.05) and the I² statistic (>50%). Results: From 12 studies (450 patients), the pooled sustained virological response (SVR) was 71.4% (95% CI 64.7-77.4; Q statistic = 22.20, p = 0.023, I² = 50.44). The rapid virological response (RVR; 7 studies, 196 patients) was 47.4% (95% CI 40.6-54.7), and the early virological response (EVR; 9 studies, 283 patients) was 82.8% (95% CI 67.0-92.0). The probability of an SVR was 93.1% (95% CI 84.9-97.0) in those who obtained an RVR (6 studies, 82 patients) and 85.9% (95% CI 78.7-91.0) if an EVR (7 studies, 168 patients) was reached. Conclusion: Peginterferon with ribavirin is an effective option for treating acute HCV in HIV-positive patients, especially if they achieve an RVR or an EVR.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

“…Two studies used 12 months between positive and negative serologies in their definition [44,46]. One study used 3 months [38], another used 8 months [6], and a third used 2 years [44].…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Treatment of Acute Hepatitis C Infection with Pegylated Interferon and Ribavirin in Patients Coinfected with Human Immunodeficiency Virus: A Systematic Review and Meta-Analysis

Zhang

Nguyen²,

Yee³

et al. 2015

Intervirology

View full text Add to dashboard Cite

show abstract

Update on HIV/HCV Coinfection

Soriano¹,

Vispo²,

Fernández-Montero³

et al. 2013

Curr HIV/AIDS Rep

View full text Add to dashboard Cite

Liver disease is currently one of the leading causes of hospitalization and death in HIV-positive individuals. Coinfection with the hepatitis C virus (HCV) is a major contributor to this trend. Besides hepatic damage, which is enhanced in the presence of HIV-associated immunosuppression, HCV may contribute to disease in coinfected individuals by potentiating immune activation and chronic inflammation, which ultimately account for an increased risk of cardiovascular events, kidney disease, and cancers in this population. Fortunately, hepatitis C therapeutics has entered a revolutionary era in which we hope that most patients treated with the new oral direct-acting antivirals (DAA) will be cured. However, many challenges preclude envisioning a prompt elimination of HCV from the coinfected population. Issues that should be addressed include the following: (1) rising incidence of acute hepatitis C in men who have sex with men, and expansion/recrudescence of injection drug use in some settings/regions; (2) adverse drug interactions between antiretrovirals and DAA; and (3) high cost of DAA, which may lead many to defer or fail to access appropriate therapy.

show abstract

Consequence of HIV and HCV co-infection on host immune response, persistence and current treatment options

et al. 2018

View full text Add to dashboard Cite

Hepatitis C virus (HCV) is a common opportunistic pathogen especially among Human immunodeficiency virus (HIV) infected patients. Due to incongruous studies, the pathological effect of HCV on HIV induced disease are still not fully understood. While some studies have showed no effect of HCV on HIV infection, others reported a defined role of HCV in aggravating the rates of AIDS-related illnesses and mortality. The explanation of such variances may be due to the host immune response, viral genotypes, sub-type and quasi-species distribution. The factors that complicate the management of HIV/HCV patients are: (1) reduced HCV antibody production, (2) drug interactions, (3) liver disease and (4) different epidemiologic characteristics. However, it is abundantly clear that the morbidity and mortality caused by HCV have increased since the introduction of highly active antiretroviral therapy (HAART) against HIV. In this review, the consequence of HIV/HCV co-infection on host immune response, viral replication, disease progression, mortality and morbidity, viral load, persistence and current treatment options have been discussed. Based on the clinical studies, it is necessary to evaluate the effect of HCV therapy on HIV progression and to provide a fully active HCV treatment for patients receiving HIV treatment. In conclusion, it is recommended to provide fully active HAART therapy in combination with a known HCV therapy.

show abstract

Spontaneous clearance and treatment of acute hepatitis C infection in HIV-positive men with 48 weeks of interferon-alpha and Ribavirin

Cited by 13 publications

References 32 publications

Treatment of Acute Hepatitis C Infection with Pegylated Interferon and Ribavirin in Patients Coinfected with Human Immunodeficiency Virus: A Systematic Review and Meta-Analysis

Treatment of Acute Hepatitis C Infection with Pegylated Interferon and Ribavirin in Patients Coinfected with Human Immunodeficiency Virus: A Systematic Review and Meta-Analysis

Update on HIV/HCV Coinfection

Consequence of HIV and HCV co-infection on host immune response, persistence and current treatment options

Contact Info

Product

Resources

About